News | January 30, 2015

FDA Approves Study of SynCardia Total Artificial Heart for Destination Therapy

19 patients not eligible for donor heart transplant will participate in the clinical study to evaluate the SynCardia Total Artificial Heart for permanent use

January 30, 2015 — SynCardia Systems Inc. has received U.S. Food and Drug Administration (FDA) approval to conduct a clinical study of the effectiveness of the SynCardia temporary Total Artificial Heart for permanent use, also called destination therapy.

On December 18, 2014, the FDA approved the SynCardia Investigational Device Exemption (IDE) application to conduct the study in 19 patients who do not qualify for a donor heart transplant.

Clinically stable patients implanted with the SynCardia Total Artificial Heart will receive the FDA-approved Freedom portable driver, which powers the SynCardia Heart and allows patients increased mobility. The SynCardia Total Artificial Heart is implanted in patients who are dying of end-stage biventricular heart failure in which the two ventricles of the native heart cannot pump enough blood for the patient to survive.

Similar to a donor heart transplant, the SynCardia Total Artificial Heart replaces the native heart’s two failed ventricles and four valves. It is the only approved device that eliminates the source of end-stage biventricular heart failure.

Because of the growing demand for donor hearts, and the flat supply, many patients live for months or years supported by the SynCardia Total Artificial Heart. The longest a person has lived with the SynCardia Heart was 1,374 days—nearly four years—before his donor heart was successfully transplanted.

For more information: www.syncardia.com

 

 

Related Content

Medtronic Announces Global Resolute Onyx DES One-Month DAPT Study
News | Antiplatelet and Anticoagulation Therapies| August 18, 2017
Medtronic plc announced a global randomized clinical trial that will evaluate one-month dual antiplatelet therapy (DAPT...
Bivalirudin exhibited an improvement in 30-day all-cause mortality when injected post PCI.
News | Antiplatelet and Anticoagulation Therapies| August 16, 2017
August 16, 2017 — A study has examined the efficacies of various post-percutaneous coronary intervention (PCI) bivali
ESC 2017 late breaking trial hot line study presentations.
News | Clinical Study| August 16, 2017
Aug. 16, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking Clinic
News | Drug-Eluting Balloons| August 15, 2017
Surmodics Inc. announced receipt of an investigational device exemption (IDE) from the U.S. Food and Drug...
The Vascular Dynamics MobiusHD device enhances the carotid baroreceptors to reduce resistant hypertension.
News | Hypertension| August 15, 2017
Aug. 15, 2017 — The U.S. Food and Drug Administration (FDA) has approved the Vascular Dynamics Inc.
Abbott Initiates First Clinical Trial of Clip-Based Tricuspid Repair System
News | Heart Valve Technology| August 09, 2017
Abbott announced that the first patient has been enrolled in a clinical study to evaluate a minimally invasive clip-...
Three New Atrial Fibrillation Studies to Feature HeartLight Endoscopic Ablation System
News | Ablation Systems| August 07, 2017
CardioFocus Inc. announced that its HeartLight Endoscopic Ablation System is being featured in three new major clinical...
Registry Identifies Early Onset of Heart Failure and Lack of Defibrillators in Asia
News | Heart Failure| August 03, 2017
August 3, 2017 — The Asian Pacific Society of Cardiology (ASPC) held its first-ever late-breaking...
Overlay Init